Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trialAxel Bauer, Uwe Dorwarth, Michael Schreinlechner et al.|The Lancet Respiratory Medicine|2021Cited by 104
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” studyMathias Jachs, Péter Ferenci, K Dax et al.|Alimentary Pharmacology & Therapeutics|2022Cited by 73
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)Mattias Mandorfer, Thomas Reiberger, Elmar Aigner et al.|Wiener klinische Wochenschrift|2023Cited by 61